Angiogenesis is the process by which new blood vessels are formed from pre-existing vasculature, being a key process that leads to tumour development. Some studies recognize phenolic compounds as chemopreventive agents; flavonoids, in particular seem to suppress the growth of tumor cells modifying the cell cycle. Herein, the antiangiogenic activity of Roman chamomile (Chamaemelum nobile L.) extracts (methanolic extract and infusion) and the main phenolic compounds present (apigenin, apigenin-7-O-glucoside, caffeic acid, chlorogenic acid, luteolin, luteolin-7-O-glucoside) was evaluated through enzymatic assays using the tyrosine kinase intracellular domain of the Vascular Endothelium Growth Factor Receptor-2 (VEGFR-2), which is a transmembrane receptor expressed fundamentally in endothelial cells involved in angiogenesis, and molecular modelling studies. The methanolic extract showed a lower IC 50 value (concentration that provided 50% of VEGFR-2 inhibition) than the infusion, 269 and 301 µg/mL, respectively. Regarding phenolic compounds, luteolin and apigenin showed the highest capacity to inhibit the phosphorylation of VEGFR-2, leading us to believe that these compounds are involved in the activity revealed by the methanolic extract.
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Introduction
Angiogenesis is the process by which new blood vessels are formed from pre-existing vasculature, developing a hemovascular network. 1 It is tightly controlled by a balance of angiogenesis factors and inhibitors, occurring in the embryonic development, wound healing and the female reproductive cycle. Angiogenic diseases result from new blood vessels growing either excessively (e.g. cancer, diabetic retinopathy and psoriasis) or insufficiently (e.g. chronic wounds and ischaemic heart disease). 1, 2 During angiogenesis, endothelial cells degrade the basement membrane, migrate into the surrounding intercellular matrix, proliferate to form new blood vessels, and differentiate into contiguous tubular sprouts, which subsequently form functional capillary loops. Such cellular events are mediated by various intracellular signal transduction pathways. 3, 4 Angiogenesis happens in the body all the time. It occurs through a so-called angiogenesis "cascade" which involves a series of biochemical steps by which cells make and secrete molecules that initiate the growth of capillaries. After the process is over, certain other molecular "factors" turn off the angiogenesis process.
Cancer cells use this normal process for another purpose-creating an imbalance of angiogenesis activators that overrides the inhibitors and gives the nearby tumour ready access to a blood supply. 5 This explains why angiogenesis is essential for the growth, progression, and metastasis of solid tumours. 6 In the mentioned pathophysiological processes, excessive angiogenesis occurs when diseased cells produce abnormally large amounts of angiogenesis factors [e.g. vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF)-2 and hepatocyte growth factor], overwhelming the effects of natural angiogenesis inhibitors (e.g.
angiostatin,endostatin and thrombospondin). 1 VEGF is a secreted growth factor by tumor cells that plays a critical role in angiogenesis; low oxygen tension dramatically induces the expression of this major angiogenic factor. 7 Its biologic effects are mediated by two receptor tyrosine kinases namely VEGFR-1 (fms-like tyrosine kinase, Flt-1) and VEGFR-2 (kinase-insert domain-containing receptor, KDR), which differ considerably in their signalling characteristics. 8, 9 Although increasing evidence indicates that angiogenesis is a highly sophisticated and coordinated process, the activation of the VEGF/VEGFR pathway remains the key modulator of angiogenesis. 10 Furthermore, VEGF is the leading angiogenic factor involved in tumoral angiogenesis. 7.9 Of the primary receptors, VEGFR-2 is thought to mediate the majority of tumor angiogenic effects (Figure 1a ). Current clinical treatments against tumor antiangiogenesis that target VEGFR-2 include: monoclonal antibodies (e.g. bevacizumab) that target the VEGFR-2 extracellular VEGF binding domain and small tyrosine kinase inhibitors (TKIs) that target the VEGFR-2 intracellular tyrosine kinase domain (Figure 1b) . TKIs act by binding to the ATP binding pocket and to adjacent pockets thus preventing the phosphorylation of this intracellular domain (e.g., sunitinib, sorafenib, ZD6474, erlotinib or thalidomide) and blocking the angiogenic signaling pathway (Figure 1c) , lowering blood tumoral irrigation, and improving chemotherapy distribution. 9 Several polyphenolic compounds are recognized as cancer chemopreventive agents.
Flavonoids are especially well known to suppress tumor cell growth via cell-cycle arrest and by the induction of apoptosis in several tumor cell lines. 11, 12 Moreover, flavonoids namely genistein inhibit endothelial cell cultures on collagen gels. 13 Antiangiogenic effect of apigenin on tumor cells was also reported and related to a reduction in the expression of VEGF. 12 Other plant-derived anticancer drugs (e.g. Taxol®, camptothecin and combretastatin) proved to be antiangiogenic. In traditional Chinese medicine, many herbs are used in the treatment of angiogenic diseases such as chronic wounds and rheumatoid arthritis. 1 Furthermore, it has been reported that drinking green tea could inhibit VEGF-induced angiogenesis in vivo. 5 In a previous work, we reported the antitumor activity of Roman chamomile An infusion was also prepared from the lyophilized plant material. The sample (1 g) was added to 200 mL of boiling distilled water and left to stand at room temperature for 5 min, and then filtered under reduced pressure. The obtained infusion was frozen, lyophilized and re-dissolved in DMSO to a final concentration of 400 µg/mL.
Materials and methods

2.1.Biological material and samples preparation
Phenolic compounds
Apigenin, Apigenin-7-O-glucoside, caffeic acid, chlorogenic acid, luteolin, luteolin-7-O-glucoside were from Extrasynthese (Genay, France). Each phenolic compound was dissolved in DMSO to a final concentration of 40 µg/mL.
VEGFR-2 enzymatic inhibition assay
C. nobile methanolic extract and infusion, and the pure phenolic compounds were assessed for VEGFR-2 inhibition activity using the Z'-LYTE-Tyr1 Peptide assay kit (Invitrogen, Cat. PV3190) according to the procedures recommended by the manufacturer. 15 Briefly, assays were performed in a total of 20 µL in 384-well plates using fluorescence resonance energy transfer technology. A Tyr1 substrate (coumarin-fluorescein double-labeled peptide) at 1 µM was incubated for 1h with 4 µg/mL VEGFR-2, 50 µM ATP and the C. nobile methanolic extract/infusion (400 at 6.25 µg/mL) or the pure phenolic compounds (40 at 0.04 µg/mL) at room temperature in 50 mM Hepes/NaOH (pH 7.5), 10 mM MgCl 2 , 2 mM MnCl 2 , 2.5 mM DTT, 0.1 mM morthovanadate, and 0.01% bovine serum albumin. The wells were incubated at 25 ºC for 1h and 5 µL development reagents were added to each well. After a second incubation of 1h a stop reagent was added to each well. Using a Biotek FLX800 microplate the fluorescence was read at 445 nm and 520 nm (excitation 400 nm), and Gen5™
Software was used for data analysis. Ginestein (Extrasynthese, Genay, France) was used as positive control.
The assays were performed in triplicate and the results were expressed as mean values ± standard deviation (SD). The results were analyzed using a Student´s t-test with α = 0.05, to determine the significant difference among the two extracts. For the phenolic compounds, the analysis was performed using one-way analysis of variance (ANOVA) followed by Tukey's HSD Test with α = 0.05. These treatments were carried out using SPSS v. 22.0 program.
Docking simulations using AutoDockVina
The 2D structure of the compounds apigenin, apigenin-7-O-glucoside, luteolin and luteolin-7-O-glucoside was constructed using the ACD/ChemSketch Freeware 12.0 software. Open Babel 16 was used to convert compounds from 2D to 3D and saved in pdb format.
A VEGFR-2 crystal structure (PDB: 2XIR) was extracted from the Protein Data Bank (PDB) (http://www.rcsb.org). The co-crystallized ligand was extracted from the PDB file, and AutoDockTools 17 was used to assign polar hydrogens and Gasteiger charges to the compounds and VEGFR-2 protein. All structures were saved in PDBQT file format required to use AutoDockVina. 18 AutodockVina was used to perform docking in an area of 30 Å by 30 Å by 30 Å, centered on the co-crystallized ligand. The docking simulations were performed on a cluster of 6 AMD Opteron 6128 8 core 2.0 GHz with using MOLA software. 19 All figures with structure representations were prepared using PyMOL (The PyMOL Molecular Graphics System, Version 1.3, Schrödinger, LLC. Available at:
(http://www.pymol.org/). Accessed on 03 September, 2012.
Molecular Dynamics Simulation
The 
Results and Discussion
According to previous studies of the authors, Roman chamomile is an equilibrated valuable species rich in carbohydrates and proteins, and poor in fat, providing tocopherols, carotenoids and essential fatty acids (C18:2n6 and C18:3n3). Moreover, the herb and its infusion are a source of phenolic compounds and organic acids with a high bioactive potential. 14 Herein, methanolic extract, infusion and phenolic compounds of Roman chamomile were evaluated for their ability to interact with the VEGFR-2 kinase domain, using an enzymatic (Fluorescence resonance energy transfer) FRETbased assay. The results are given in Table 1 .
The methanolic extract showed a lower IC 50 value than the infusion, 269 and 301 µg/mL, respectively. These results are in agreement with the higher phenolic compounds amount, antioxidant and antitumor activities also previously reported for the methanolic extract. 14 should be highlighted that the methanolic extract prepared from the herb would provide even higher amounts of those derivatives (21.31 and 13.50 µg/mL, respectively 14 ).
Regarding
The possible VEGFR-2 inhibition mechanism of luteolin, apigenin and apigenin-7-Oglucoside (Figure 2) was predicted using docking tools. A careful analysis of the predicted docking poses showed that apigenin and luteolin probably interacts with VEGFR-2 ATP binding site with a similar binding pose, stabilized by three predicted hydrogen bonds (Figure 3) (Figure 4) .
After small adjustments in the first ns of the MD simulation, both apigenin and luteolin structures remained stable thought-out the duration of the MD simulation with average RMSD of 0.37 and 0.57 Å, respectively (Figure 4) . This is an indication that the predicted docking pose is reliable and is probably close to the experimental VEGFR-2 binding pose. In both MD simulations, the RMSD values for the VEGFR-2 backbone structure was also analyzed and it was observed that, after a normal adjustment of around 2 ns, the RMSD values also remained stable thought-out the rest of the MD simulation. This is the expected MD simulation behavior of the protein backbone indicating that the VEGFR-2 structure used is suitable for this type of molecular modeling studies.
In general the MD simulations performed give us further assurance that the predicted docking pose probably corresponds closely to the experimental binding pose although this can only be completely established by the elucidation of the VEGFR-2/apigenin or VEGFR2/luteolin complex structures, usually performed by X-ray crystallography.
The antiangiogenic effect of apigenin on tumor cells was already reported but related to a reduction in the expression of VEGF 12 and not with an inhibition of VEGFR activity, such it was demonstrated in the present work. Regarding luteolin, as far as we know this is the first report on antiangiogenic activity, being only reported its anticarcinogenic effects mainly by induction of apoptosis and cell cycle arrest by action on critical molecular targets for cell survival such as p53, p21, cyclin dependent kinases and caspases in liver 21 and non-small cell lung 22 cancer cells. 
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